PATENT CLAIM ANALYSIS

Application Number: 16095269
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "450000"]

Abstract:
According to the present disclosure, the use of a liposomal formulation comprising one or more phospholipids in the manufacture of a medicament, or in a method for the treatment of posterior and/or anterior ocular segment diseases is provided. Preferred phospholipids include POPC and DOTAP, POPC and POPG, DPTAP and POPG, DMTAP and POPG, DPPC and DPTAP, DPPC and DPPG, DMPC and DMTAP, or DMPC and DMPG. In a separate embodiment, the use of a particulate formulation comprising a plurality of poly(lactic-co-glycolic acid) particles in the manufacture of a medicament, or in a method for the treatment of posterior and/or anterior ocular segment diseases is also provided. In either embodiments, the posterior ocular segment diseases comprise age related degeneration, diabetic macular edema or retinopathy and anterior ocular segment diseases comprise glaucoma, cataract or uveitis.

Claim (Index 24):
The method according to  claim 23 , wherein the combination comprises POPC and DOTAP, POPC and POPG, DPTAP and POPG, DMTAP and POPG, DPPC and DPTAP, DPPC and DPPG, DMPC and DMTAP, or DMPC and DMPG.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 2.26471
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15253307', '15320903', '15101523', '10558563', '15922433']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7894919700086068
- 35 USC 102 Novelty (BERT): 0.5386687025328194
- Combined Prediction Score: 0.7644096432610281
- Mean Citation Score: 342.927994
- Max Citation Score: 378.17783
- Similarity Product: 247.2712206641204

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test